Cell Therapeutics (CTIC) Stock May 5, 2009

This morning, 5/5/09, Cell Therapeutics, Inc. (CTIC) released news regarding one of their drugs. In pre market trading, CTIC shares are up 19% to $0.56 and breaking out.

CTIC News - 5/5/09

CTIC Stock Forum - www.stockstobuy.org


Pixantrone Now Available in Europe on a Named-Patient Basis

--Cell Therapeutics and IDIS Partner to Accelerate Patient Access to Pixantrone through Program

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that pixantrone is now available on a named-patient basis in Europe. Pixantrone will be supplied by IDIS to healthcare professionals for the treatment of individual patients with aggressive non-Hodgkin's lymphoma (NHL) that has either relapsed after standard therapies or is refractory to them. We know of no therapy that has previously been shown to be effective treatment for such patients.

"CTI has worked hard to make pixantrone available in Europe at the prescriber's request as it provides an option for these difficult to treat aggressive NHL patients," noted Craig Philips, President of CTI. "We continue to work toward potential approval of pixantrone at the end of 2009 in the United States and expect to complete the submission of the New Drug Application to the Food & Drug Administration this quarter." Full Article

Today's Biggest Stock Market Gainers - Top 2009 Stock Gainers - Top 2009 Penny Stocks

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free